Key Takeaways
- Jaguar Health has initiated an investigator-initiated trial (IIT) for crofelemer in microvillus inclusion disease (MVID).
- The study is being conducted at Sheikh Khalifa Medical City, UAE, a leading medical center in pediatric gastroenterology.
- Proof-of-concept (POC) data is expected in H1 2025, potentially leading to early patient access in Europe.
Jaguar Health Inc. (NASDAQ: JAGX) has announced the first patient dosing in an investigator-initiated proof-of-concept trial evaluating crofelemer for the treatment of microvillus inclusion disease (MVID), a severe, life-threatening pediatric disorder. Conducted at Sheikh Khalifa Medical City in Abu Dhabi, this study aims to assess crofelemer’s ability to manage chronic diarrhea and malabsorption in children with MVID.
MVID, a rare genetic disease, requires intensive parenteral nutrition, and currently has no approved treatments. Jaguar Health’s crofelemer, an FDA- and EMA-designated Orphan Drug, is a plant-based prescription therapy that has previously shown promise in managing severe gastrointestinal disorders.
Potential for Early Patient Access in Europe
The trial results, expected in H1 2025, could support early patient access programs in certain European countries, depending on clinical outcomes. This study is part of Jaguar Health’s broader research efforts, which include multiple Phase 2 studies and investigator-initiated trials for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF).
With MVID affecting only a few hundred children worldwide, this trial marks a significant step in addressing unmet medical needs and expanding treatment options for pediatric patients with rare diseases.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
